Needham Maintains Buy on NextCure, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has maintained a Buy rating on NextCure (NASDAQ:NXTC) but has reduced the price target from $6 to $4.
December 14, 2023 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Needham has maintained a Buy rating on NextCure but lowered the price target from $6 to $4, indicating a potential downside compared to the previous target.
The reduction in price target by Needham suggests that they see less upside potential for NextCure's stock price in the short term. This could lead to a negative investor sentiment and a potential decrease in the stock price as the new target is set lower than the previous one.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100